After Keytruda Deaths, FDA Hits Pause On Bristol-Myers Squibb's Opdivo Myeloma Trials

After Keytruda deaths, FDA hits pause on Bristol-Myers Squibb’s Opdivo myeloma trials

After patient deaths cropped up in multiple myeloma studies featuring Merck’s Keytruda, the FDA isn’t taking any chances with the med’s rival, Bristol-Myers Squibb’s Opdivo.

Continue reading on FiercePharma